The kaposi sarcoma therapeutics pipeline is expected to grow rapidly as the disease also has the risk of the patient being infected with Acquired Immune Deficiency Syndrome (AIDS). AIDS is the most common risk factors of kaposi sarcoma, which develops in people who are infected with HIV. The Kaposi sarcoma therapeutics pipeline is expected to generate large revenue due to increasing awareness regarding cancer treatments, high demand for safe and effective medications, advancement in technologies and increasing prevalence of cancer and immunodeficiency syndrome. The American Cancer Society and other regulatory bodies are supporting the Kaposi sarcoma pipeline by providing increased funding and grants.
According to American Cancer Society, Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in the other parts of the body, such as in the lymph nodes (bean-sized collections of immune cells throughout the body), the lungs, or digestive tract. The abnormal cells of kaposi sarcoma form purple, red, or brown blotches or tumors on the skin. These affected areas are called lesions. The skin lesions of Kaposi sarcoma most often appear on the legs or face. They may look bad, but they usually cause no symptoms. At times, some lesions on the legs or in the groin area may cause the legs and feet to swell painfully.
Many companies have a pipeline of drugs for the treatment of Kaposi sarcoma, which are under clinical development. Vasgene Therapeutics, Inc plans to introduce a recombinant EphB4-HSA fusion protein, which is currently in Phase II. Recombinant EphB4-HSA fusion protein showed a promising result in blocking growth of blood vessels that provide blood to cancer. Apogee Biotechnology Corporation also plans to introduce a drug ABC294640, which is currently in Phase I clinical development for treatment of Kaposi sarcoma. Chiltern International Inc. plans to introduce a biological, XmAb13676, which is currently in Phase I clinical development. XmAb13676 is a monoclonal antibody expected to target CD20 expressing malignancies.
As conventional methods of treatment of kaposi sarcoma, certain chemotherapy medications, such as Capecitabine, Cisplatin, Fluorouracil and Gemcitabine have been well established. Nevertheless, immunotherapy, combination therapy, monoclonal antibodies and steroids are also offering effective results for the treatment of Kaposi sarcoma. Kaposi sarcoma is a rare disease so, increasing awareness regarding the treatment has been driving the pipeline growth. However, high cost of treatment and the side effects associated with the treatment options act as key barriers that are hindering the growth of the pipeline. Around 48,330 new case of kaposi sarcoma, with estimated deaths standing at 9,570 were reported in the U.S., in 2016.
Some of the companies having a pipeline of kaposi sarcoma therapeutics include Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffman-La Roche, AG, GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Merck & Co., Inc.